Editas Medicine Announces U.S. Patent and Trademark Office Grants the Broad Institute Priority Benefit in CRISPR InterferenceGlobeNewsWire • 09/11/20
Editas Medicine Receives Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Sickle Cell DiseaseGlobeNewsWire • 08/24/20
Editas Medicine, Inc. (EDIT) CEO Cindy Collins on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/07/20
Here's Why Shares of Editas Medicine and Beam Therapeutics Are Soaring TodayThe Motley Fool • 08/06/20
Earnings Preview: Editas Medicine (EDIT) Q2 Earnings Expected to DeclineZacks Investment Research • 07/30/20
Catalent Enters into Strategic Partnership with Editas Medicine to Support Gene Editing Medicine PipelineGlobeNewsWire • 07/29/20
Editas Medicine to Host Conference Call Discussing Second Quarter 2020 Results and Corporate UpdateGlobeNewsWire • 07/23/20
Editas Medicine and Azzur Group Announce a Multi-year Agreement for EDIT-301 and EDIT-201 ManufacturingGlobeNewsWire • 07/07/20
Editas Medicine Announces Closing of Offering of Common Stock and Full Exercise by Underwriter of Option to Purchase Additional SharesGlobeNewsWire • 06/26/20
Editas Medicine Presents Pre-Clinical Data from a Study of EDIT-301 with Sickle Patient Cells for the Potential Treatment of Sickle Cell DiseaseGlobeNewsWire • 06/12/20
Editas (EDIT) Up 10.6% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 06/06/20